A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Trial Profile

A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs IMGN 779 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors ImmunoGen
  • Most Recent Events

    • 12 Dec 2017 Results (n=26) assessing initial safety and antileukemia activity from the dose escalation phase of the study, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Dec 2017 New data from this trial presented in an ImmunoGen media release.
    • 01 Nov 2017 According to an ImmunoGen media release, updated data evaluating the safety and anti-leukemia activity from the dose escalation phase of this trial will be presented at the American Society of Hematology (ASH) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top